Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
PeerJ. 2024 Jul 12;12:e17696. doi: 10.7717/peerj.17696. eCollection 2024.
The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated.
In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.
A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43-13.33]) months and the median overall survival was 16.8 (95% CI [13.3-27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure.
WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.
全脑放疗(WBRT)加同步整合推量(SIB)在乳腺癌脑转移中的疗效尚未得到证实。
在这项单中心回顾性研究中,我们回顾了连续接受适形调强放疗(IMRT)-SIB 方法的低分割放疗加 WBRT 治疗脑转移的乳腺癌患者。我们分析了临床结果、预后因素和治疗失败模式。
共有 27 例患者符合分析条件。4 例(14.8%)患者的脑转移病灶达到临床完全缓解,14 例(51.9%)患者有部分缓解。其他 9 例患者未进行脑肿瘤反应评估。脑无进展生存期的中位数为 8.60 个月(95%CI[6.43-13.33]),总生存期的中位数为 16.8 个月(95%CI[13.3-27.7])。3 例患者发生场内失败,5 例患者发生场外失败,2 例患者发生场内和场外失败。
WBRT 加 SIB 可改善乳腺癌脑转移患者的肿瘤控制和临床结局。